HUTCHMED Secures NMPA Approval for ATLED in FGFR2-Altered Cholangiocarcinoma
HCM sits 29% above its 52-week low of $9.77.
Summary
HUTCHMED received NMPA conditional approval for ATLED (fanregratinib) to treat FGFR2-altered intrahepatic cholangiocarcinoma, backed by strong Phase II efficacy data including 42.5% ORR and 16.6-month median OS.
Key Events · Product Development and Regulatory · HCM
-
NMPA Conditional Approval for ATLED
China's NMPA granted conditional approval to ATLED (fanregratinib) for adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have received prior systemic therapy.
-
Strong Phase II Efficacy Data
The approval is supported by a Phase II registration cohort showing IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%), DCR of 83.9%, median PFS of 6.9 months, and median OS of 16.6 months in pretreated patients.
-
Fourth Marketed Medicine in China
ATLED becomes HUTCHMED's fourth medicine marketed in China, following the July 2026 NMPA approval of ORPATHYS for MET-amplified gastric cancer, expanding the company's commercial oncology portfolio.
-
Confirmatory Phase IIIb Underway
Enrollment for the Phase IIIb confirmatory cohort was initiated in January 2026; this study will be required to convert the conditional approval to full approval.
Analysis · HCM · Life Sciences
China's NMPA has granted conditional approval to ATLED (fanregratinib) for pretreated advanced intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The approval is backed by a 42.5% objective response rate and 16.6-month median overall survival in a patient population with historically limited targeted options. This marks HUTCHMED's second NMPA approval in under two months, following ORPATHYS for gastric cancer in July, and the company's fourth marketed medicine in China. The Phase IIIb confirmatory cohort is already enrolling, which will be required to convert the conditional approval to full approval.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $12.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.77 to $18.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.